ID   NCC-MFS4-C1
AC   CVCL_B3RL
DR   Wikidata; Q110433086
RX   PubMed=34383271;
WW   https://en.cellline.jp/product/ncc-mfs4-c1/
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo T.).
CC   Doubling time: ~64 hours (PubMed=34383271).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Unspecified (PubMed=34383271).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Unspecified (PubMed=34383271).
CC   Omics: SNP array analysis.
CC   Derived from site: In situ; Lower leg, hypodermis; UBERON=UBERON_0003823+UBERON_0002072.
ST   Source(s): PubMed=34383271
ST   Amelogenin: X
ST   CSF1PO: 13
ST   D13S317: 8
ST   D16S539: 10
ST   D21S11: 29,32.2
ST   D5S818: 12
ST   D7S820: 11,12
ST   TH01: 6
ST   TPOX: 8,12
ST   vWA: 14,17
DI   NCIt; C6496; Myxofibrosarcoma
DI   ORDO; Orphanet_79105; Myxofibrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   65Y
CA   Cancer cell line
DT   Created: 16-12-21; Last updated: 30-01-24; Version: 5
//
RX   PubMed=34383271; DOI=10.1007/s13577-021-00589-x;
RA   Yoshimatsu Y., Noguchi R., Tsuchiya R., Sin Y., Ono T., Sugaya J.,
RA   Iwata S., Yoshida A., Kawai A., Kondo T.;
RT   "Establishment and characterization of NCC-MFS4-C1: a novel
RT   patient-derived cell line of myxofibrosarcoma.";
RL   Hum. Cell 34:1911-1918(2021).
//